Brovana
Brovana (arformoterol tartrate) is a sterile, clear, colorless, long-acting beta2-adrenergic agonist (LABA) inhalation solution. It works by relaxing the muscles around the airways in the lungs, helping to keep them open and make breathing easier. It is intended only for long-term control of COPD and should not be used as a rescue medication for acute breathing problems.
Dosage by Body Weight
The standard dose is one 15 mcg unit-dose vial administered twice daily (once in the morning and once in the evening) using a standard jet nebulizer connected to an air compressor. Do not exceed 30 mcg per day.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Brovana is not approved for pediatric use. Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Brovana is not approved for pediatric use. Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Brovana is not approved for pediatric use. Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Brovana is not approved for pediatric use. Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Brovana is not approved for pediatric use. Safety and effectiveness in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | N/A | Brovana is not approved for pediatric use. Safety and effectiveness in pediatric patients have not been established. |
| 5-7 kg | Not indicated | N/A | Brovana is not approved for pediatric use. Safety and effectiveness in pediatric patients have not been established. |
| 8-10 kg | Not indicated | N/A | Brovana is not approved for pediatric use. Safety and effectiveness in pediatric patients have not been established. |
| 11-15 kg | Not indicated | N/A | Brovana is not approved for pediatric use. Safety and effectiveness in pediatric patients have not been established. |
| 16-20 kg | Not indicated | N/A | Brovana is not approved for pediatric use. Safety and effectiveness in pediatric patients have not been established. |
Formulation
Purpose
Long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Generic Name
Arformoterol tartrateScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.